These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22894664)

  • 1. Targeting survivin's co-conspirators: do alternative methods of trapping survivin in the nucleus have potential in triple-negative breast cancer therapy?
    Holloway MP; Altura RA
    Future Oncol; 2012 Aug; 8(8):907-9. PubMed ID: 22894664
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple-negative breast cancer.
    Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
    [No Abstract]   [Full Text] [Related]  

  • 3. Search for new treatments intensifies for triple-negative breast cancer.
    Brower V
    J Natl Cancer Inst; 2009 Nov; 101(22):1536-7. PubMed ID: 19880812
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 5. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targets in triple negative breast cancer.
    O'Toole SA; Beith JM; Millar EK; West R; McLean A; Cazet A; Swarbrick A; Oakes SR
    J Clin Pathol; 2013 Jun; 66(6):530-42. PubMed ID: 23436929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
    Bershteĭn LM
    Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
    [No Abstract]   [Full Text] [Related]  

  • 9. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
    Voduc D; Nielsen TO
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
    Zhang B
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):241-4. PubMed ID: 21575491
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From the guest editor: Triple-negative breast cancer.
    Hudis CA
    Cancer J; 2010; 16(1):10-1. PubMed ID: 20164684
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer in focus: treatment options for triple-negative metastatic breast cancer.
    O'Shaughnessy JA
    Clin Adv Hematol Oncol; 2012 Jan; 10(1):43-5. PubMed ID: 22398807
    [No Abstract]   [Full Text] [Related]  

  • 18. Few positives for triple-negative breast cancer.
    Hede K
    J Natl Cancer Inst; 2011 Apr; 103(7):532-3. PubMed ID: 21436063
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
    Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
    Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches for triple-negative breast cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):916, 931, 935. PubMed ID: 23175999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.